1. Medicine

Category Archives: Medicine

Penn Medicine Experts Available for Comment on Latest Research at SLEEP 2013

Posted on by

PHILADELPHIA - Perelman School of Medicine at the University of Pennsylvania clinicians and researchers will be presenting compelling data and giving talks about emerging issues in the field of sleep medicine during SLEEP 2013, in Baltimore, MD, June 2 5, 2013.

In addition to their own presentations, Penn experts are available for interviews and outside comment in the following areas:

Obstructive Sleep Apnea

Allan Pack, MBChB, PhD Chief, Division of Sleep Medicine and Director, Center for Sleep and Respiratory Neurobiology

Dr. Packs clinical expertise is in sleep disorders with a particular focus on diagnosis and management of obstructive sleep apnea. His research focuses on the genetics/genomics of sleep and its disorders. His laboratory is conducting studies in Drosophila and mice and translating these findings to humans. A particular focus of Dr. Packs work is to evaluate the genetic determinants of sleep homeostasis.

Chronobiology and Sleep Loss/Deprivation

David F. Dinges, PhD - Professor and Chief, Division of Sleep and Chronobiology in the Department of Psychiatry

Dr. Dinges laboratory is dedicated to scientific discovery of the physiological, cognitive and functional changes resulting from sleep loss and behavioral stressors in humans, and to evaluating behavioral, pharmacological and technological countermeasures to these effects. His research has involved extensive laboratory, simulator and field studies on the consequences of sleep loss and circadian misalignment from both lifestyle and medical disorders; effects of sleep disorders; recovery potential of naps; nature of sleep inertia; impact of cumulative sleep debt; differential vulnerability to the neurobehavioral effects of sleep loss; and development of technologies for monitoring human neurobehavioral capability.

Sleep and General Health

Michael Grandner, PhD Instructor, Department of Psychiatry and Member, Behavioral Sleep Medicine Program

Go here to see the original:

Penn Medicine Experts Available for Comment on Latest Research at SLEEP 2013

Annual Conference to Address Key Operational and Business Concerns of Genomic Medicine

Posted on by

KEENE, N.H.--(BUSINESS WIRE)--

G2 Intelligence a 30+ year leader in research, reporting, and analysis on the business of the diagnostic lab industry today announced the final agenda for MDx NEXT, with dynamic sessions, case studies, and interactive panel discussions surrounding the theme: Gaining Ground in Molecular Testing and Genomic Medicine. G2s annual event will be held in a new city at a new venue this year: the Westin Las Vegas Hotel Casino & Spa, June 12-14, 2013.

Everyone with a stake in molecular diagnostics can look forward to expert insight and advice on how clinical laboratories of all sizes are successfully using molecular testing, despite the challenging regulatory and ever-changing business environments, said Stephanie Murg, G2s Managing Director and conference program chair. In fact, with genomic medicine firmly established and growing rapidly, the time is ideal for labs to find out how they can actively harness the evolving markets clinical utility, latest technology, and novel business models to grow. This years conference is dedicated to that purpose.

Industry professionals who want to know where the market is headed wont want to miss this years conference, continues Kimberly Scott, G2s Managing Editor and program co-chair. The agenda is oriented toward a broad range of labs, and will also tackle such hot-button topics as reimbursement, building a more cost-effective test menu, and the prospects for next-generation sequencing.

Confirmed sessions to include:

Attendees are encouraged to make the most of their experience with one or both pre-conference workshops on Wednesday, June 12:

MDx NEXT keynote speakers are:

Distinguished faculty in attendance to include:

To find out more, or to register for G2s MDx NEXT conference, go to http://www.MDxConference.com, call 1-800-531-1026, or email customerservice@G2Intelligence.com.

Group discounts are available for 3 or more people from the same organization. For group registrations, please call Jeff Watkins at 973-718-4709 to facilitate your registration, or email jwatkins@G2Intelligence.com.

More here:

Annual Conference to Address Key Operational and Business Concerns of Genomic Medicine

Convocation address Johns Hopkins University School of Medicine May 23, 2013 – Video

Posted on by


Convocation address Johns Hopkins University School of Medicine May 23, 2013
Jon Lorsch, Ph.D., Professor of Biophysics and Biophysical Chemistry, delivers the keynote address at the Johns Hopkins University School of Medicine Convoca...

By: Johns Hopkins Medicine

Go here to read the rest:

Convocation address Johns Hopkins University School of Medicine May 23, 2013 - Video

GOCC Sabbath Class: Spiritual Healing vs. Frankenstein Medicine {Part 9} finale’ – Video

Posted on by


GOCC Sabbath Class: Spiritual Healing vs. Frankenstein Medicine {Part 9} finale #39;
Gathering of Christ Church Phone: 888*334*3330 Email: gatheringas1@aol.com http://www.gatheringofchrist.org/ Blogtalkradio: http://m.blogtalkradio.com/gocchu...

By: Judah #39;s Back

Read more from the original source:

GOCC Sabbath Class: Spiritual Healing vs. Frankenstein Medicine {Part 9} finale' - Video

Editorial: Noble motives behind UW Medicine-PeaceHealth partnership

Posted on by

AN agreement between the University of Washingtons medical system and Catholic-sponsored PeaceHealth should not be mistaken for a merger. Mergers between secular and religious hospitals, which often dont provide abortion care or end-of-life services, has been a trend that threatens to make those services harder to access.

The mission of the proposed strategic affiliation between UW Medicine and PeaceHealth is noble and deserves a chance to work. Together they wrote off a combined $425 million in charity care last year.

But many questions remain.

In the era of health-care reform, academic institutions like UW Medicine rely on partnerships to advance science, train the next generation of health-care providers and improve patient outcomes. Community hospitals like PeaceHealth need a place to send patients for care they arent able to provide.

As the organizations codifythe terms of an informal network, they should also work to ease tensions and answer the concerns of many in the communities they serve.

How will they reconcile inherent differences in their missions? UW Medicine offers the full spectrum of health services. PeaceHealth limits abortion care and prohibits end-of-life services within its facilities.

Will UW students be trained to provide comprehensive care in PeaceHealth settings? If not, where will that learning occur?

What is PeaceHealths relationship with the Catholic church? The letter of intent makes no mention of religion. Ignoring this important affiliation on paper invites suspicion.

Are there long-term implications? The American Civil Liberties Union of Washington warns similar agreements have led to hospitals being taken over by Catholic organizations. Though PeaceHealth is independent today, its officials negotiated with the more conservative Catholic Health Initiatives to blend operations. Talks were suspended in April, but critics are leery of their public pledge to strengthen their respective ministries in the Pacific Northwest.

Maximum transparency and clarity would strengthen the UW Medicine-PeaceHealth affiliation and help them fulfill the greater goal of building a healthy community.

Read more:

Editorial: Noble motives behind UW Medicine-PeaceHealth partnership

Scientists taking Chinese medicine west

Posted on by

By Pamela Boykoff, CNN

updated 8:07 PM EDT, Mon May 27, 2013

STORY HIGHLIGHTS

Hong Kong (CNN) -- At Chi-Med's labs in Shanghai, a group of 70 chemists has been working for a decade to try and crack the mysteries of Chinese medicine.

The company's scientists are attempting to break 1,300 medicinal herbs into their component parts and then test them for global use against diseases.

It's an ambitious effort and one that looks close to paying off. Chi-Med, in partnership with Nestle, has started the first worldwide phase III clinical testing trials -- the final step before approval for sale -- for a botanical drug based on Chinese Traditional Medicine.

If Chi-Med and Nestle succeed in winning U.S. Food and Drug Administration (FDA) approval, the companies will be at the forefront of efforts to export Chinese medicine beyond its loyal following at home. They'll also have tackled the central problem in taking Chinese medicine global: how do you get a centuries-old remedy through the rigors of modern government regulation?

"The simpler the product, the better at this stage," says Chi-Med CEO Christian Hogg. "The more similar it is to conventional drugs, the better from the FDA standpoint." That's why the company has started with a drug called HMPL-004, which treats inflammatory bowel disease (IBD) including ulcerative colitis and Crohn's disease.

The testing was made possible by a change in the FDA policies and procedures in 2004 regarding botanical drug products.

The new guidelines removed some of the obstacles involved in getting an investigational new drug application (IND), the first step in getting a drug developed and marketed in the U.S.

Visit link:

Scientists taking Chinese medicine west


  1. Medicine